Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Update – Notification regarding unquoted securities – RAD

Friday, March 7, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared regarding four ongoing programs.
Price reaction · baseline $6.53 (2025-03-06 close) · hit pre-market · clean, no other RADX news in the window
day 0 close
-1.8%
day 1
-5.8%
day 3 · peak
-14.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Announcements
• March 7, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• May 30, 2025
• Announcements
• June 22, 2022
• Announcements
• April 22, 2024
• Announcements
• December 12, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the latest update from Radiopharm Theranostics?

Radiopharm Theranostics has dosed the first patient in its Phase 1/2a clinical study of BetaBart.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3.

What are the key programs mentioned in the update?

The update highlights positive clinical progress across four ongoing programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Mar 7, 2025